Data from Incyte’s Oncology Portfolio to be Featured at the 2019 ESMO Congress
3.9.2019 15:14:00 EEST | Business Wire | Press release
Incyte (Nasdaq:INCY) announces that abstracts highlighting data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain from September 27-October 1, 2019.
Results from FIGHT-202, a Phase 2 study of pemigatinib as a second-line treatment for patients with advanced/metastatic or surgically unresectable cholangiocarcinoma, including updated safety and efficacy data in patients with FGFR2 fusions or rearrangements, as well as genomic profiling and correlations with clinical outcomes will be presented. Results from the Phase 1 study of INCB001158, an arginase inhibitor being developed with Calithera Biosciences, alone and in combination with pembrolizumab as a treatment for advanced or metastatic solid tumors, will also be presented.
“Incyte is committed to advancing treatments that have the potential to address areas of high unmet need and we look forward to sharing data on our investigational therapies with the oncology community at ESMO 2019,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Data from the Phase 2 FIGHT-202 study assessing pemigatinib as a potential treatment for cholangiocarcinoma are encouraging and may represent an important step forward for patients in urgent need of effective treatment options.”
Abstracts will be available on the ESMO Congress website at https://www.esmo.org/Conferences/ESMO-Congress-2019.
Oral Presentations:
FIGHT-202: a Phase 2 study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) (Abstract #2550, proffered paper session)
- Friday, September 27, 2019 from 3:00 p.m. CEST to 3:15 p.m. CEST (9 a.m. ET to 9:15 a.m. ET) in Madrid Auditorium (Hall 2)
Phase 1 study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (Adv/Met) solid tumors (Abstract #1621, oral abstract session)
- Sunday, September 29, 2019 from 4:54 p.m. CEST to 5:06 p.m. CEST (10:54 a.m. ET to 11:06 a.m. ET) in Malaga Auditorium (Hall 5)
Poster Details:
Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the FIGHT-202 trial (Abstract #2078, poster session)
- Sunday, September 29, 2019 from 12:00 p.m. CEST to 1:00 p.m. CEST (6:00 a.m. ET to 7:00 a.m. ET) in Poster Area (Hall 4)
Full session details and data presentation listings for ESMO 2019 can be found at: https://cslide.ctimeetingtech.com/esmo2019/attendee.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s ongoing clinical development programs for pemigatinib and an arginase inhibitor as monotherapy and in combination with pembrolizumab and the potential of such programs, including the potential for pemigatinib to treat cholangiocarcinoma, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2019. The Company disclaims any intent or obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005491/en/
Contact information
Incyte Contacts
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RecVue Launches First AI Native Agentic Revenue Operating System21.7.2026 16:03:00 EEST | Press release
RecVue, the leader in billing and revenue management solutions, today announced the evolution of RecVue RevOS into the industry's first Agentic Revenue Operating System. In an architectural shift, the now-native agentic revenue management platform moves revenue operations beyond AI-assisted workflows to fully governed, autonomous execution with more than 50 purpose-built agents that work across contracts, invoices and payment data to predict risk, surface anomalies and escalate exceptions throughout the quote-to-cash lifecycle. Enterprise revenue operations have long suffered from a structural gap between billing systems that generate invoices and ERP systems that record transactions. Finance teams face tedious, manual reconciliation month after month, often resulting in delayed cash, billing errors that generate disputes, revenue leakage from ungoverned contract changes and close cycles that consume weeks. “Enterprise RevOps has always demanded both speed and precision, but traditiona
Yubico Extends Passkeys Beyond Trusted Authentication to Verified Authorization with Launch of YubiKey 5.821.7.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the original passkey, the YubiKey, today announced the general availability of its YubiKey 5.8 – marking an expansion of the role of the passkey from secure authentication to include verifiable, hardware-backed authorization. The new firmware delivers a foundation for secure enterprise workflows across identity wallets, document signing, and AI-driven approvals, while also providing developers with the critical capabilities needed to test, design and deploy these next-generation security features early. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721286409/en/ As generative and agentic AI mature to drive rapid, automated cyberattacks, traditional multi-factor authentication (MFA) is failing to keep pace. Security leaders now face a challenge globally: securing not just who logs into a system, but exactly what actions a us
Gurobi Publishes Inaugural State of Mathematical Optimization in Academia Report21.7.2026 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the publication of its inaugural State of Mathematical Optimization in Academia Report. Based on surveys of over 1,180 faculty and students who actively use Gurobi, the report examines how optimization is being taught, used in research, and applied across academia today—as well as use cases that could benefit from a combination of generative AI (GenAI) with optimization. Gurobi’s research highlights the importance of making optimization education and tools accessible to students and instructors. “Mathematical optimization is powering some of the most effective decision-making across today’s enterprises, and the academic community is key to advancing its theory and practice,” said Duke Perrucci, CEO, Gurobi. “By exploring how students, researchers, and educators are teaching and applying optimization—especially in tandem with evolving GenAI solutions—we can better support the next generation of dec
ExaGrid Announces a Record Bookings and Revenue Quarter21.7.2026 15:00:00 EEST | Press release
ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it had a record quarter of bookings and revenue in the second quarter ending June 30, 2026, with double-digit revenue growth over Q2 of 2025 and double-digit revenue growth for the first six months of 2026 over 2025. In addition, ExaGrid remained P&L, EBITDA, and free cash flow positive for the 22nd consecutive quarter. The company is 100% debt-free, demonstrating strong financial health as a company. ExaGrid added 207 new customers in Q2 2026, including 99 six- and seven-figure new customer deals in the quarter, with five of those over $1M each. Highlights of Q2 2026: Strong competitive win rate at over 80% for the quarter. Brought on 207 new customers. 99 six- and seven-figure new logo customer deals. Over 5,200 organizations protect their data with ExaGrid Tiered Backup St
Alpaca Launches German Equities Trading via Deutsche Börse Xetra21.7.2026 14:00:00 EEST | Press release
Alpaca, a global leader in agent-first brokerage infrastructure, today announced that its broker partners can now offer trading in German equities through Deutsche Börse Xetra, providing access to one of Europe’s largest equity markets. The launch marks the first phase of Alpaca’s broader global equities initiative. In the coming months, Alpaca expects to roll out access to additional major international exchanges, including Hong Kong Stock Exchange, London Stock Exchange, Saudi Exchange, Euronext Paris, and Korea Exchange, with additional markets planned. Germany is the largest economy in Europe and the third largest in the world, behind the United States and China. Through Xetra, Alpaca’s broker partners can offer access to hundreds of German equities, including shares in companies such as SAP, Siemens, Allianz, BMW, Deutsche Bank, Adidas, and Bayer, across sectors including technology, manufacturing, financial services, and healthcare. "Investors increasingly expect access beyond U.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom